ResMed Inc.RMD
Health Care · Health Care Equipment & Services · NYSE · United States · resmed.com
ResMed Inc. develops, manufactures, and distributes cloud-connected medical devices and software solutions for the diagnosis and treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory disorders. The company also provides software-as-a-service solutions for out-of-hospital care settings, serving patients, physicians, and healthcare systems globally.
Key ratios
Operating cash flow growth
3.1%TTM
2026
3.1%2025
25.0%2024
102.1%
EPS growth
9.7%TTM
2026
9.7%2025
37.4%2024
13.6%
FCF / Sales
29.2%TTM
2026
29.2%2025
32.3%2024
27.8%2023
13.6%
Net margin
26.9%TTM
2026
26.9%2025
27.2%2024
21.8%2023
21.3%
ROA
14.8%TTM
2026
14.0%2025
14.0%2024
12.7%2023
12.2%
ROE
24.3%TTM
2026
24.3%2025
25.9%2024
22.7%2023
24.0%
Revenue growth
9.9%TTM
2026
9.9%2025
9.8%2024
11.0%
Recent news
Resmed Announces Participation in the 24th Annual Morgan Stanley Global Healthcare Conference
23XI Racing NASCAR Driver Tyler Reddick Reveals Sleep Apnea Diagnosis, Teams Up With ResMed to Help Others Recognize the Signs
Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026
Resmed completes $340M Noctrix takeover
Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
Track RMD in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer